BCL2L10

Across TCGA pan-cancer cohorts, BCL2L10 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BCL2L10 data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher BCL2L10 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL2L10 expression acts as an unfavorable survival marker.

SCLC and BLCA are the cancer types where BCL2L10 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.602	.008	18	view →
BLCA	DFS	Median	III,IV	0.132	0.572	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BCL2L10–SCLC (DFS)

Open the SCLC breakdown →